Esperion Therapeutics, Inc. (ESPR)

$1.99

-0.14

(-6.57%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Esperion Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 33.96M → 32.25M (in $), with an average decrease of 5.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -41.25M → -56.34M (in $), with an average decrease of 36.6% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 40.7% return, outperforming this stock by 133.3%

Performance

  • $1.95
    $2.10
    $1.99
    downward going graph

    2.01%

    Downside

    Day's Volatility :6.92%

    Upside

    5.01%

    downward going graph
  • $0.70
    $3.40
    $1.99
    downward going graph

    64.82%

    Downside

    52 Weeks Volatility :79.41%

    Upside

    41.47%

    downward going graph

Returns

PeriodEsperion Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
0.0%
1.1%
0.0%
6 Months
191.62%
12.5%
0.0%
1 Year
76.03%
6.9%
2.2%
3 Years
-92.58%
14.3%
-23.0%

Highlights

Market Capitalization
395.8M
Book Value
- $3.85
Earnings Per Share (EPS)
-2.03
PEG Ratio
-4.78
Wall Street Target Price
7.41
Profit Margin
-179.87%
Operating Margin TTM
-131.37%
Return On Assets TTM
-42.86%
Return On Equity TTM
-260.79%
Revenue TTM
116.3M
Revenue Per Share TTM
1.13
Quarterly Revenue Growth YOY
71.39999999999999%
Gross Profit TTM
-70.4M
EBITDA
-155.4M
Diluted Eps TTM
-2.03
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.4
EPS Estimate Next Year
0.05
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.04

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Esperion Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 272.36%

Current $1.99
Target $7.41

Company Financials

FY18Y/Y Change
Revenue
184.5M
-
Net Income
-201.8M
↑ 20.85%
Net Profit Margin
-109.4%
-
FY19Y/Y Change
Revenue
148.4M
↓ 19.57%
Net Income
-109.0M
↓ 45.98%
Net Profit Margin
-73.48%
↑ 35.92%
FY20Y/Y Change
Revenue
227.5M
↑ 53.37%
Net Income
-166.2M
↑ 52.44%
Net Profit Margin
-73.04%
↑ 0.44%
FY21Y/Y Change
Revenue
78.4M
↓ 65.52%
Net Income
-318.8M
↑ 91.84%
Net Profit Margin
-406.42%
↓ 333.38%
FY22Y/Y Change
Revenue
75.5M
↓ 3.79%
Net Income
-287.8M
↓ 9.73%
Net Profit Margin
-381.34%
↑ 25.08%
FY23Y/Y Change
Revenue
116.3M
↑ 54.14%
Net Income
-209.2M
↓ 27.3%
Net Profit Margin
-179.87%
↑ 201.47%
Q3 FY22Q/Q Change
Revenue
19.0M
↑ 0.74%
Net Income
-68.6M
↓ 14.53%
Net Profit Margin
-361.49%
↑ 64.56%
Q4 FY22Q/Q Change
Revenue
18.8M
↓ 0.85%
Net Income
-68.5M
↓ 0.22%
Net Profit Margin
-363.81%
↓ 2.32%
Q1 FY23Q/Q Change
Revenue
24.3M
↑ 29.29%
Net Income
-89.2M
↑ 30.32%
Net Profit Margin
-366.72%
↓ 2.91%
Q2 FY23Q/Q Change
Revenue
25.8M
↑ 5.99%
Net Income
-49.9M
↓ 44.03%
Net Profit Margin
-193.65%
↑ 173.07%
Q3 FY23Q/Q Change
Revenue
34.0M
↑ 31.73%
Net Income
-41.3M
↓ 17.39%
Net Profit Margin
-121.43%
↑ 72.22%
Q4 FY23Q/Q Change
Revenue
32.3M
↓ 5.06%
Net Income
-56.3M
↑ 36.59%
Net Profit Margin
-174.71%
↓ 53.28%
FY18Y/Y Change
Total Assets
143.5M
↓ 48.37%
Total Liabilities
64.3M
↑ 94.1%
FY19Y/Y Change
Total Assets
214.4M
↑ 49.49%
Total Liabilities
194.5M
↑ 202.33%
FY20Y/Y Change
Total Assets
353.3M
↑ 64.73%
Total Liabilities
449.4M
↑ 131.05%
FY21Y/Y Change
Total Assets
381.6M
↑ 8.02%
Total Liabilities
578.5M
↑ 28.74%
FY22Y/Y Change
Total Assets
247.9M
↓ 35.02%
Total Liabilities
571.7M
↓ 1.18%
FY23Y/Y Change
Total Assets
205.8M
↓ 17.0%
Total Liabilities
660.8M
↑ 15.58%
Q3 FY22Q/Q Change
Total Assets
312.8M
↑ 2.91%
Total Liabilities
606.9M
↑ 1.89%
Q4 FY22Q/Q Change
Total Assets
247.9M
↓ 20.74%
Total Liabilities
571.7M
↓ 5.8%
Q1 FY23Q/Q Change
Total Assets
251.8M
↑ 1.56%
Total Liabilities
581.5M
↑ 1.71%
Q2 FY23Q/Q Change
Total Assets
234.6M
↓ 6.83%
Total Liabilities
606.6M
↑ 4.32%
Q3 FY23Q/Q Change
Total Assets
221.3M
↓ 5.68%
Total Liabilities
631.3M
↑ 4.07%
Q4 FY23Q/Q Change
Total Assets
205.8M
↓ 7.01%
Total Liabilities
660.8M
↑ 4.67%
FY18Y/Y Change
Operating Cash Flow
-148.6M
↑ 13.2%
Investing Cash Flow
140.4M
↓ 491.74%
Financing Cash Flow
10.7M
↓ 93.46%
FY19Y/Y Change
Operating Cash Flow
-70.3M
↓ 52.68%
Investing Cash Flow
64.2M
↓ 54.27%
Financing Cash Flow
136.2M
↑ 1173.56%
FY20Y/Y Change
Operating Cash Flow
-85.2M
↑ 21.09%
Investing Cash Flow
21.4M
↓ 66.75%
Financing Cash Flow
201.7M
↑ 48.11%
FY21Y/Y Change
Operating Cash Flow
-263.8M
↑ 209.72%
Investing Cash Flow
-50.5M
↓ 336.39%
Financing Cash Flow
268.2M
↑ 32.96%
FY22Y/Y Change
Operating Cash Flow
-174.8M
↓ 33.73%
Investing Cash Flow
8.1M
↓ 116.05%
Financing Cash Flow
32.6M
↓ 87.84%
Q3 FY22Q/Q Change
Operating Cash Flow
-42.8M
↓ 15.24%
Investing Cash Flow
33.0M
↑ 560.0%
Financing Cash Flow
46.3M
↑ 155.64%
Q4 FY22Q/Q Change
Operating Cash Flow
-42.5M
↓ 0.84%
Investing Cash Flow
-11.8M
↓ 135.74%
Financing Cash Flow
-30.4M
↓ 165.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-54.4M
↑ 27.98%
Investing Cash Flow
25.0M
↓ 311.97%
Financing Cash Flow
49.5M
↓ 263.03%
Q2 FY23Q/Q Change
Operating Cash Flow
-24.8M
↓ 54.47%
Investing Cash Flow
17.5M
↓ 30.0%
Financing Cash Flow
809.0K
↓ 98.37%

Technicals Summary

Sell

Neutral

Buy

Esperion Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
-18.7%
191.62%
76.03%
-92.58%
-95.06%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-1.55%
28.4%
35.29%
40.71%
79.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.71%
1.58%
-6.07%
12.69%
12.69%
Zoetis Inc.
Zoetis Inc.
-10.09%
-7.81%
-12.8%
-11.14%
48.17%
Viatris Inc.
Viatris Inc.
-2.37%
28.76%
25.82%
-14.76%
-29.31%
Catalent, Inc.
Catalent, Inc.
-0.8%
41.9%
32.08%
-51.64%
25.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
NA
NA
-4.78
-0.4
-2.61
-0.43
NA
-3.85
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.72
56.72
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
30.04
30.04
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
Buy
$395.8M
-95.06%
NA
-179.87%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
79.5%
56.72
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.4B
12.69%
30.04
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.17%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-29.31%
225.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
25.36%
211.02
-31.77%

Institutional Holdings

  • Wasatch Advisors Inc.

    4.80%

  • Two Seas Capital LP

    4.15%

  • Vanguard Group Inc

    2.78%

  • Bellevue Group AG

    2.27%

  • Meditor Group Ltd

    2.05%

  • Millennium Management LLC

    1.86%

Corporate Announcements

  • Esperion Therapeutics, Inc. Earnings

    Esperion Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.

Organization
Esperion Therapeutics, Inc.
Employees
240
CEO
Mr. Sheldon L. Koenig
Industry
Health Technology

Discover More

FAQs